




FIG. 1

2/80







FIG. 1 cont'd

3/80

A**B****FIG. 2**

4/80




FIG. 2 cont'd

5/80






FIG. 3


6/80




Covariate	HR (95% CI)	P-value
8 genes Score (high, low)	2.6267 (1.3695 - 5.0378)	0.0038
Lymph node (+, -)	0.9409 (0.4327 - 2.0459)	0.8785
Grade (1, 2, 3)	1.0276 (0.7178 - 1.4713)	0.8826
ER (+, -)	0.9833 (0.5223 - 1.8512)	0.9587



Covariate	HR (95% CI)	P-value
8 genes Score (high, low)	2.2123 (1.4438 - 3.3910)	0.0003
ER (+, -)	1.5586 (0.9834 - 2.5214)	0.072



Covariate	HR (95% CI)	P-value
8 genes Score (high, low)	2.1445 (1.0906 - 4.2176)	0.015
Lymph node (+, -)	2.8619 (1.5138 - 5.0751)	0.0003
ER (+, -)	0.5962 (0.2470 - 1.4394)	0.2526
Grade (1, 2, 3)	1.2947 (0.8032 - 2.0869)	0.2914
p53 (mut, WT)	1.2607 (0.6670 - 2.3825)	0.478



Covariate	HR (95% CI)	P-value
8 genes Score (high, low)	3.4442 (1.5914 - 7.4540)	0.0018
Lymph node (+, -)	5.4825 (1.7112 - 18.753)	0.0044
Tumor size (1, 2, 3)	1.6679 (1.0037 - 2.7718)	0.0496
ER (+, -)	1.6261 (0.7056 - 3.7473)	0.2561
Grade (1, 2, 3)	0.8233 (0.4698 - 1.4435)	0.4996
PR (+, -)	1.2716 (0.5865 - 2.7581)	0.5448

FIG. 4

7/80




FIG. 5




FIG. 6

8/80







FIG. 7

A**Comparison of All Genes Across 8 Analyses****FIG. 8**

B**Comparison of All Genes Across 7 Analyses****Overexpression****Underexpression****Legend**

1. Breast Carcinoma - Metastatic Event at 5 Years
Bos Breast, Nature, 2009

2. Invasive Ductal Breast Carcinoma - Metastatic Event at 5 Years
Desmedt Breast, Clin Cancer Res, 2007


3. Invasive Breast Carcinoma - Metastatic Event at 5 Years
Hatzis Breast, JAMA, 2011

4. Breast Carcinoma - Metastatic Event at 5 Years
Kao Breast, BMC Cancer, 2011

5. Invasive Breast Carcinoma - Metastatic Event at 5 Years
Schmidt Breast, Cancer Res, 2008

6. Invasive Breast Carcinoma - Metastatic Event at 5 Years
Symmans Breast, J Clin Oncol, 2010

7. Breast Carcinoma - Metastatic Event at 5 Years
vandeVijver Breast, N Engl J Med, 2002




The rank for a gene is the median rank for that gene across each of the analyses.
The p-Value for a gene is its p-Value for the median-ranked analysis.

Copyright© 2008-11 Compendia Bioscience, Inc. Images from OncoPrint™ may be used in publications with proper citation.
The citation for OncoPrint is as follows: OncoPrint™ (Compendia Bioscience, Ann Arbor, MI) was used for analysis and visualization.
For further information, refer to the terms described in the license agreement.

FIG. 8 cont'd


C Comparison of All Genes Across 7 Analyses



Copyright© 2008-11 Compendia Bioscience, Inc. Images from OncoPrint™ may be used in publications with proper citation.
The citation for OncoPrint is as follows: OncoPrint™ (Compendia Bioscience, Ann Arbor, MI) was used for analysis and visualization.
For further information, refer to the terms described in the license agreement.

FIG. 8 cont'd

12/80

**FIG. 9**











FIG. 10

A**B****FIG. 11**

15/80




FIG. 12




FIG. 13

17/80




FIG. 14

18/80




FIG. 15

19/80




FIG. 15 cont'd

20/80




FIG. 15 cont'd




FIG. 16




FIG. 17

23/80




FIG. 18

24/80




FIG. 19

25/80




FIG. 20

26/80





FIG. 21

27/80



	Univariate Cox-proportional hazards model			Multivariate Cox-proportional hazards model		
	HR	95 % CI	p-value	HR	95 % CI	p-value
TN score (high vs. low)	2.9993	1.2533-7.1778	0.0141	3.3316	1.2323-9.0069	0.0183
Stage (I, II, III)	3.4112	1.2738-9.1355	0.0151	3.2814	0.8902-12.095	0.0757
Nodal status (N0, N1)	3.4618	1.2525-9.5680	0.0172	0.9415	0.2092-4.2375	0.9377
HER2 (Neg, Pos)	0.3487	0.0456-2.6680	0.3127			
Age (<50, >50)	1.2375	0.4502-3.4018	0.6812			
Tumor size (T2/3 vs T1)	1.0393	0.2916-3.7046	0.9528			

FIG. 22




FIG. 23

29/80




FIG. 24

30/80




FIG. 25

31/80




FIG. 26




FIG. 27

33/80




FIG. 28




FIG. 29

35/80




FIG. 30

36/80




FIG. 30 cont'd

A Comparison of All Genes Across 7 Analyses




FIG. 31

B Comparison of All Genes Across 7 Analyses




FIG. 31 cont'd





FIG. 32

**FIG. 33**




FIG. 34

42/80





FIG. 35

43/80



C. Subtraction







FIG. 36 cont'd

45/80

ER- breast cancer



ER+ breast cancer












FIG. 37




FIG. 38

47/80




FIG. 38 cont'd




FIG. 39




FIG. 40

50/80




FIG. 41




FIG. 42




FIG. 43

53/80




FIG. 44




FIG. 45

55/80




FIG. 46

56/80




FIG. 47





FIG. 48

58/80




FIG. 48 cont'd

59/80




FIG. 48 cont'd

60/80




FIG. 49

61/80

B	Parameter	Univariate Cox-proportional hazard model			Multivariate Cox-proportional hazard model		
		HR	95% CI	P	HR	95% CI	P
	Combined IBCR mRNA/Protein Score (Q1, Q2, Q3, Q4)	1.75	1.45 - 2.12	<0.0001	3.46	1.51 - 7.92	0.0035
	Stage (I, IIA, IIB, IIIA, IIIB, IIIC)	1.49	1.15 - 1.92	0.0023	3.81	1.30 - 11.17	0.0153
	Tumor size (T1, T2, T3)	1.12	0.81 - 1.55	0.5094	3.88	0.72 - 20.53	0.1157
	HER2 (pos vs. neg)	1.82	1.01 - 3.28	0.0466	6.24	0.43 - 9.34	0.1816
	Radiotherapy (yes vs. no)	0.38	0.19 - 0.76	0.0083	0.27	0.04 - 1.98	0.1991
	PAM50 subtypes	1.08	0.87 - 1.34	0.5048	0.69	0.36 - 1.34	0.2804
	Lymph node (pos vs. neg)	2.14	1.35 - 3.39	0.0012	3.32	0.33 - 3.38	0.3127
	ER (pos vs. neg)	0.76	0.48 - 1.21	0.2493	0.40	0.22 - 7.49	0.5439
	Age at Dx (<50 vs. >50)	0.60	0.37 - 0.95	0.0295	0.28	0.04 - 2.32	0.5775
	Surgery (lump, mastec, mod. rad. mastec., Other)	1.28	1.04 - 1.58	0.0191	0.75	0.27 - 2.12	0.5901
	Molecular therapy (no vs. yes)	6.17	2.63 - 14.43	<0.0001	1.62	0.17 - 15.91	0.6805
	Histology (ILC vs. IDC)	0.53	0.23 - 1.22	0.1399	0.54	0.27 - 10.69	0.6847
	PR (pos vs. neg)	0.76	0.49 - 1.16	0.2035	0.72	0.414 - 1.25	0.8219
	Menopause (post vs. pre)	2.04	1.03 - 4.05	0.0419	1.15	0.15 - 8.65	0.9483

FIG. 49 cont'd




FIG. 50

E

Covariate	HR	95% CI	P
Combined iBCR mRNA/Protein (Q1-Q4)	2.08	1.24 - 3.50	0.0056
Age (<60, 60-70, >70)	2.25	1.14 - 4.43	0.0198
Nodal status (N1 vs. N0)	1.73	1.40 - 2.10	0.0254
Tumor size (T1, T2, T3, T4)	1.63	0.83 - 3.19	0.1553
Residual tumor (yes vs. no)	3.70	0.46 - 30.06	0.2229
EGFR (mut vs. WT)	2.43	0.46 - 12.87	0.2995
Stage (Stage I, II, III)	0.58	0.11 - 3.03	0.5197
Targeted therapy (yes vs. no)	1.96	0.25 - 14.29	0.5218
Gender (F or M)	1.32	0.35 - 4.96	0.6797
KRAS (mut vs. WT)	1.33	0.25 - 7.01	0.7403
PIK3CA (mut vs. WT)	0.79	0.09 - 7.07	0.8321
ERBB4 (mut vs. WT)	0.84	0.11 - 6.72	0.8714
mRNA Subtype (Bronchioid, Magnoid, Squamoid)	0.98	0.54 - 1.78	0.9520




FIG. 50 cont'd

64/80

Kidney renal clear cell carcinoma (KIRC)




FIG. 51

65/80

Skin cutaneous melanoma (SKCM)




FIG. 51 cont'd

66/80

Uterine corpus endometrioid carcinoma (UCEC)




FIG. 51 cont'd

67/80

Ovarian adenocarcinoma (OVAC)




FIG. 52

68/80

Head & Neck squamous cell carcinoma (HNSC)




FIG. 52 cont'd

69/80

Colon/Rectal Adenocarcinoma (COREAD)




FIG. 52 cont'd

70/80

Lower Grade Glioma (LGG)




FIG. 53

71/80

Bladder urothelial carcinoma (BLCA)




FIG. 53 cont'd

72/80

Lung squamous cell carcinoma (LUSC)




FIG. 53 cont'd

73/80




FIG. 54

74/80




FIG. 55





FIG. 56

76/80

**FIG. 56 cont'd**


**FIG. 57**

FIG. 58

79/80




FIG. 58 cont'd

80/80




FIG. 59